Physician profile
Ya Li Lin
NPI 1053518548
$1,083.69
in general payments reported to CMS, 2019-2025
8 companies · $686 in 2025
The $686 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2023: $213 · 2024: $75.55 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $974.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $407.51 | 2023-2025 | Repatha, Otezla, Repatha |
| Gilead Sciences, INC. | $250.00 | 2023-2025 | Vemlidy, Yeztugo |
| Phathom Pharmaceuticals, INC. | $145.50 | 2025 | Voquezna |
| Lilly USA, LLC | $109.19 | 2025 | Kisunla |
| Janssen Pharmaceuticals, INC | $96.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $37.04 | 2023 | Farxiga |
| Novo Nordisk INC | $24.98 | 2023 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ya Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.